Dr. John Allan Ellerton MD, CM

Cancers are a huge focus for research. Millions of dollars every year are funneled into funding research that could improve treatment methods or find cures for cancer, including blood cancers. Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma (NHL) accounting...

Over time, research has uncovered ways of treating Hodgkin lymphoma (HL) to produce an 80% to 90% cure rate. For the remaining 10% to 20% who are either resistant to the primary treatment or have relapsed, their cancer can still be fatal.The standard care for those not yet cured has been a two-step...

Each year, Leukemia and Blood Cancer New Zealand (LBC) sponsors their Blood Cancer Patient Forum. They invite speakers to bring them news about such topics as treatment advances and management of cancer from a fully developed psycho-social perspective. Essentially, they dish up good old-fashioned...

Danny Feltwell, a young six-year-old boy, was diagnosed with T-cell lymphoblastic lymphoma when he was just two years old. After undergoing countless procedures and just four months from being considered fully cured, Danny relapsed and had to be re-hospitalized. The doctors found that a large tumor...

Many cancer patients suffer in silence, with the public being largely unaware of the different types of cancer and how they affect patients. Most people obviously know that cancer is well, a bad thing, but there is a lot of nuance and important information that is lost on the common citizen. Most...

Reuters, the international news agency out of London, has announced that the FDA has given a new drug “accelerated approval,” for the treatment of follicular lymphoma.The drug, Aliqopa (copanlisib), showed complete or partial shrinkage of tumors in 59% of study participants during drug studies,...